Covered Companies: Xenetic Biosciences
Most Recent Event
What This Means
April 9, 2025
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers.
NASDAQ: XBIO
About
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers. The Company’s DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Past Events
What This Means
December 17, 2024
Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia
What This Means
November 22, 2024
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact